ROUNDTABLE

Browse all ROUNDTABLE
Ep. 3: Time Toxicity, CNS Risk, and Sequencing Strategy in EGFR-Mutant NSCLC

ROUNDTABLE

Ep. 3: Time Toxicity, CNS Risk, and Sequencing Strategy in EGFR-Mutant NSCLC

Eric Singhi, MD, Sarah Goldberg, MD, MPH, Fawzi Abu Rous, MD, Julia Rotow, MD, Susan Scott, MD

Ep. 2: Clinical Insights: Proactive Toxicity Management and CNS Control in EGFR-Mutant NSCLC

ROUNDTABLE

Ep. 2: Clinical Insights: Proactive Toxicity Management and CNS Control in EGFR-Mutant NSCLC

Eric Singhi, MD, Sarah Goldberg, MD, MPH, Susan Scott, MD, Fawzi Abu Rous, MD, Julia Rotow, MD

Ep. 1: OS Benefit and Patient-Centered Delivery Advances in EGFR-Mutant NSCLC

ROUNDTABLE

Ep. 1: OS Benefit and Patient-Centered Delivery Advances in EGFR-Mutant NSCLC

Eric Singhi, MD, Susan Scott, MD, Sarah Goldberg, MD, MPH, Fawzi Abu Rous, MD, Julia Rotow, MD

INTERVIEW

Browse all INTERVIEW
Ep. 3: Intensification Strategies and CNS Management in EGFR-Mutant NSCLC

INTERVIEW

Ep. 3: Intensification Strategies and CNS Management in EGFR-Mutant NSCLC

Chinmay Jani, MD, Luis Raez, MD, FACP, FCCP, FASCO

Ep. 2: Subcutaneous Amivantamab Reshapes Frontline EGFR-Mutant NSCLC Care

INTERVIEW

Ep. 2: Subcutaneous Amivantamab Reshapes Frontline EGFR-Mutant NSCLC Care

Chinmay Jani, MD, Luis Raez, MD, FACP, FCCP, FASCO

Ep. 1: Overcoming Infusion Barriers in EGFR-Mutant Non–Small Cell Lung Cancer

INTERVIEW

Ep. 1: Overcoming Infusion Barriers in EGFR-Mutant Non–Small Cell Lung Cancer

Chinmay Jani, MD, Luis Raez, MD, FACP, FCCP, FASCO